Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Price Target at $45.25

Upstream Bio, Inc. (NASDAQ:UPB) has been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $45.25.

A number of analysts have weighed in on UPB shares. Evercore started coverage on Upstream Bio in a research report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price target on the stock. Lifesci Capital assumed coverage on shares of Upstream Bio in a research report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 target price for the company. Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st.

Institutional Investors Weigh In On Upstream Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in Upstream Bio in the fourth quarter worth $29,000. Torren Management LLC bought a new position in shares of Upstream Bio in the fourth quarter valued at about $30,000. Empowered Funds LLC acquired a new position in Upstream Bio during the 4th quarter worth about $45,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Upstream Bio during the 4th quarter worth about $71,000. Finally, Russell Investments Group Ltd. increased its position in Upstream Bio by 1,963.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock valued at $57,000 after acquiring an additional 2,887 shares in the last quarter.

Upstream Bio Trading Down 1.7%

UPB stock opened at $7.67 on Tuesday. Upstream Bio has a 1-year low of $5.14 and a 1-year high of $33.68. The business’s 50 day moving average is $22.35 and its 200-day moving average is $22.36. The firm has a market cap of $414.49 million, a P/E ratio of -4.08 and a beta of 2.96.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.